Scroll down to discover
OncoKDM is the first personalised bioinformatic assistant that can be customised to your specific needs and your bioinformatics pipeline. It is a highly-secured platform, accessible through the web which will turn your data into useful knowledge, without investment in hardware or IT staff.
OncoKDM can integrate sequencing data from any platform with any other test performed in the laboratory. Through proprietary algorithms, OncoKDM can analyse and integrate the information to enable relevant biological and clinical interpretation.
Based on its expertise in giving sense to molecular data obtained from individual cancer patient tested in routine, OncoDNA has developed a specific environment to allow clinical data integration and interpretation. Clinical background, treatment history, molecular characterisation data, treatment arm, clinical outcomes, … so many different types of data OncoDNA can extract knowledge from.
Integrate genomics, molecular pathology, IHC test results, and clinical data.
DNA (Ion Torrent, Illumina,…), RNA (microarray, transcriptome), protein (IHC, MS,…)
Compatible with third party data sets QC and biomarker calling.
Customise the bioinformatics pipeline, personalise the report according to your needs and specifications.
Secure and robust web portal giving access to data and interpretation to every eligible partner.
Standardise your data to simplify further meta-analyses.
Connect with one or a list of collaborators and share and discuss the report remotely and securely to make the right decision.
"Aiding physicians to identify HRAS and other mutations in HNSCC is an essential element of Kura’s clinical development strategy. Streamlining screening processes facilitates timely access to important medical information that could help oncologists and their patients in making treatment decisions"
The study met its predefined success criteria and has been amended to continue enrolling HRAS mutant HNSCC pts, as well as pts with SCC, other than HNSCC, with HRAS mutations into a new Cohort 3. (ESMO 22 october 2018)